This site is intended for healthcare professionals
Antiplatelet therapy in ACS: Choices and Controversies

Welcome

Read time: 270 mins
Last updated:8th Jun 2022
Published:17th Dec 2021

Acute coronary syndrome (ACS) represents a leading cause of mortality and morbidity worldwide. Antiplatelet therapy is a cornerstone of ACS management. Explore:

  • The current available antiplatelet therapies for patients with ACS
  • The challenges in antiplatelet therapy selection
  • The ESC and the ACC/AHA guidelines for treating both NSTE-ACS and STEMI

How do you select antiplatelet treatments for your patients with ACS? Explore the current available oral and intravenous antiplatelet drugs for ACS with insights on the latest clinical trials informing clinical guideline recommendations. Antiplatelet therapies for ACS include clopidogrel, ticagrelor and prasugrel, and dual antiplatelet therapy (DAPT) involving combination with aspirin. Also find out about the recent guidance on the management of ACS with antiplatelet therapy according to the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) in collaboration with the American Heart Association (AHA).

Welcome: